Why Is Regeneron Stock Sinking Monday?

Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.

FDA Drug Chief Tracey Hoeg Fired Days After After Marty Makary's Exit— Says Order Came From 'Way Above'

Tracey Beth Hoeg was fired as FDA drug division chief amid a broader Trump administration shake-up at the health department.

Merck Announces New Research From 100+ Abstracts Across 25+ Types Of Cancer From Its Oncology Portfolio And Pipeline To Be Presented At The 2026 American Society Of Clinical Oncology Annual M

Five-year follow-up data from KEYNOTE-942 underscore the continued potential of intismeran autogene (mRNA-4157 or V940) in combination with KEYTRUDA® (pembrolizumab) for patients with resected high-risk

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.

Erasca Announces Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate ERAS-0015 In Combination With Keytruda

This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of

Merck Announces Publication Of Paper Describing Unique Manufacturing Methods For Enlicitide Decanoate Oral PCSK9 Inhibitor

In this publication, Merck scientists detail the biocatalytic assembly of enlicitide using a suite of enzymes that catalyze selective peptide fragment formation, coupling, and macrocyclization. Together with efficient

Salesforce Selected by Merck Animal Health To Unify Animal Health Management Systems On Single Platform

Tempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.

S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner

AI‑powered drug discovery, strong earnings upgrades, and rising institutional flows show why healthcare may shift from 2026 laggard to breakout S&P 500 growth story.

Wells Fargo Maintains Overweight on Merck & Co, Lowers Price Target to $145

Wells Fargo analyst Mohit Bansal maintains Merck & Co (NYSE:MRK) with a Overweight and lowers the price target from $150 to $145.